Springhill Fund Asset Management HK Co Ltd bought a new position in shares of Merus (NASDAQ:MRUS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 83,800 shares of the biotechnology company's stock, valued at approximately $3,524,000. Merus makes up approximately 5.7% of Springhill Fund Asset Management HK Co Ltd's portfolio, making the stock its 9th largest position. Springhill Fund Asset Management HK Co Ltd owned 0.12% of Merus at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its position in Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 300 shares during the last quarter. Avior Wealth Management LLC acquired a new position in Merus in the 4th quarter valued at about $76,000. MML Investors Services LLC purchased a new stake in shares of Merus during the third quarter worth approximately $206,000. Gordian Capital Singapore Pte Ltd raised its position in Merus by 10.4% during the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company's stock worth $250,000 after buying an additional 470 shares during the last quarter. Finally, HighTower Advisors LLC lifted its position in Merus by 10.9% in the fourth quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company's stock valued at $337,000 after purchasing an additional 789 shares during the period. Hedge funds and other institutional investors own 96.14% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on MRUS shares. Guggenheim reiterated a "buy" rating and set a $109.00 price target on shares of Merus in a research report on Friday, March 28th. Bank of America reduced their price objective on shares of Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. HC Wainwright reaffirmed a "buy" rating and set a $85.00 price target on shares of Merus in a research report on Monday, March 3rd. Needham & Company LLC restated a "buy" rating and issued a $83.00 price objective on shares of Merus in a report on Wednesday. Finally, Wells Fargo & Company started coverage on shares of Merus in a research report on Friday, February 7th. They set an "overweight" rating and a $91.00 price target for the company. One investment analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $85.31.
Check Out Our Latest Stock Report on MRUS
Merus Stock Up 4.4 %
Shares of NASDAQ:MRUS traded up $1.69 during trading on Friday, hitting $40.31. 306,733 shares of the company traded hands, compared to its average volume of 698,252. The business's fifty day moving average is $43.62 and its 200-day moving average is $45.29. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of -10.20 and a beta of 1.02. Merus has a one year low of $33.19 and a one year high of $61.61.
Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.48. The firm had revenue of $9.14 million during the quarter, compared to the consensus estimate of $10.57 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. On average, analysts forecast that Merus will post -3.85 EPS for the current year.
About Merus
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
See Also
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
